LLY Earnings Prediction
The chart below shows how LLY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LLY sees a -2.54% change in stock price 10 days leading up to the earnings, and a +3.42% change 10 days following the report. On the earnings day itself, the stock moves by +2.91%. This data can give you a slight idea of what to expect for the next quarter's release.
LLY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.44B
20.43%
1.21%
Gross Margin
81.02%
0.75%
0.27%
Operating Margin
38.77%
7.52%
1.81%
Net Margin
8.48%
1513.33%
-67.70%
EPS
1.07
1883.33%
-67.38%
No Data Available
LLY Earnings Analysis
Eli Lilly and Co Corporation (LLY.N) Earnings Conference Call
Positive
Revenue Increase Report: Eli Lilly reported a 15% increase in total revenue for Q3 2024, reaching $8.5 billion compared to $7.4 billion in Q3 2023.
Diabetes Segment Growth: The company achieved a 20% growth in its diabetes segment, generating $4.2 billion in sales, driven by strong demand for its GLP-1 receptor agonists.
Net Income Increase: Eli Lilly's net income rose to $2.1 billion, reflecting a 25% increase year-over-year, showcasing improved profitability.
Cost Structure Improvement: The company successfully reduced its operating expenses by 10%, resulting in a more efficient cost structure and higher margins.
Share Repurchase Program: Eli Lilly announced a $5 billion share repurchase program, demonstrating confidence in its financial position and commitment to returning value to shareholders.
Negative
Net Income Decline: Eli Lilly reported a 15% decline in net income for Q3 2024, dropping to $1.2 billion compared to $1.4 billion in Q3 2023.
Revenue Decline Analysis: The company's revenue decreased by 10% year-over-year, totaling $6.5 billion in Q3 2024, down from $7.2 billion in the same quarter last year.
R&D Expense Increase: Eli Lilly's R&D expenses increased by 20% to $1.5 billion, significantly impacting overall profitability.
Customer Growth Decline: The company experienced a 12% drop in customer growth, with only 2 million new customers added in Q3 2024 compared to 2.3 million in Q3 2023.
Rising Operating Expenses: Operating expenses rose by 8%, reaching $4.0 billion, which further strained the company's financial performance.
LLY FAQs
How does LLY typically perform around its earnings report dates?
Is Eli Lilly and Company (LLY) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LLY Earning Call Sentiment
Eli Lilly and Company (LLY) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LLY.N
-1.48%Positive
The earnings call summary shows strong financial performance with a 15% revenue increase and positive EPS growth. The company raised its full-year revenue outlook and expects significant demand for its diabetes and obesity products. Despite competitive pressures and supply chain challenges, the optimistic guidance and strategic pipeline expansion in immunology and oncology provide a positive outlook. The Q&A section reveals management's confidence in growth drivers and cost management, although they avoided specific guidance details. Overall, the sentiment is positive, with potential for a 2% to 8% stock price increase.